Close

Leerink Partners Upgrades Biogen (BIIB) to Outperform

Go back to Leerink Partners Upgrades Biogen (BIIB) to Outperform

Biogen and Ionis Pharmaceuticals Announce SPINRAZA (nusinersen) Meets Primary Endpoint at Interim Analysis of Phase 3 CHERISH Study in Later-Onset Spinal Muscular Atrophy

November 7, 2016 7:30 AM EST

- Second Positive Phase 3 Study Provides Further Evidence of SPINRAZAs Efficacy and Favorable Safety Profile -

- Results Were Statistically Significant and Clinically Meaningful -

CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)-- Biogen (NASDAQ: BIIB) and Ionis Pharmaceuticals (NASDAQ: IONS) announced that SPINRAZATM (nusinersen), an investigational treatment for spinal muscular atrophy (SMA), met the primary endpoint at the interim analysis of CHERISH, the Phase 3 study evaluating SPINRAZA in later-onset (consistent with Type 2) SMA. The analysis found that children receiving SPINRAZA... More